Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

258 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Antigenicity and immunogenicity of a synthetic oligosaccharide-protein conjugate vaccine against Haemophilus influenzae type b.
Fernández-Santana V, Cardoso F, Rodriguez A, Carmenate T, Peña L, Valdés Y, Hardy E, Mawas F, Heynngnezz L, Rodríguez MC, Figueroa I, Chang J, Toledo ME, Musacchio A, Hernández I, Izquierdo M, Cosme K, Roy R, Verez-Bencomo V. Fernández-Santana V, et al. Among authors: musacchio a. Infect Immun. 2004 Dec;72(12):7115-23. doi: 10.1128/IAI.72.12.7115-7123.2004. Infect Immun. 2004. PMID: 15557635 Free PMC article.
Ratio of HCV structural antigens in protein-based vaccine formulations is critical for functional immune response induction.
Martínez-Donato G, Musacchio A, Alvarez-Lajonchere L, Acosta-Rivero N, Amador Y, Guerra I, Peña D, Pérez A, Castro J, Puentes P, Soria Y, Cosme K, Sanchez J, Dueñas-Carrera S. Martínez-Donato G, et al. Among authors: musacchio a. Biotechnol Appl Biochem. 2010 Jul 9;56(3):111-8. doi: 10.1042/BA20090216. Biotechnol Appl Biochem. 2010. PMID: 20515441
Immunization with a recombinant fowlpox virus expressing a hepatitis C virus core-E1 polyprotein variant, protects mice and African green monkeys (Chlorocebus aethiops sabaeus) against challenge with a surrogate vaccinia virus.
Alvarez-Lajonchere L, Amador-Cañizares Y, Frías R, Milian Y, Musacchio A, Guerra I, Acosta-Rivero N, Martínez G, Castro J, Puentes P, Cosme K, Dueñas-Carrera S. Alvarez-Lajonchere L, et al. Among authors: musacchio a. Biotechnol Appl Biochem. 2008 Oct;51(Pt 2):97-105. doi: 10.1042/BA20070182. Biotechnol Appl Biochem. 2008. PMID: 18215116
Expression in Escherichia coli of the lpdA gene, protein sequence analysis and immunological characterization of the P64k protein from Neisseria meningitidis.
Guillén G, Alvarez A, Silva R, Morera V, González S, Musacchio A, Besada V, Coizeau E, Caballero E, Nazabal C, Carmenate T, González LJ, Estrada R, Támbara Y, Padrón G, Herrera L. Guillén G, et al. Among authors: musacchio a. Biotechnol Appl Biochem. 1998 Jun;27(3):189-96. Biotechnol Appl Biochem. 1998. PMID: 9664678
Specific active immunotherapy with a VEGF vaccine in patients with advanced solid tumors. results of the CENTAURO antigen dose escalation phase I clinical trial.
Gavilondo JV, Hernández-Bernal F, Ayala-Ávila M, de la Torre AV, de la Torre J, Morera-Díaz Y, Bequet-Romero M, Sánchez J, Valenzuela CM, Martín Y, Selman-Housein KH, Garabito A, Lazo OC; CENTAURO Group of Investigators. Gavilondo JV, et al. Vaccine. 2014 Apr 17;32(19):2241-50. doi: 10.1016/j.vaccine.2013.11.102. Epub 2014 Feb 11. Vaccine. 2014. PMID: 24530151 Clinical Trial.
258 results